Oculis (NASDAQ:OCS) Stock Price Down 4.3% – Here’s What Happened

Oculis Holding AG (NASDAQ:OCS)’s share price was down 4.3% during trading on Monday . The company traded as low as $15.34 and last traded at $15.35. Approximately 10,193 shares changed hands during mid-day trading, a decline of 72% from the average daily volume of 36,993 shares. The stock had previously closed at $16.04.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Oculis in a report on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $29.20.

Oculis Stock Up 0.5 %

The stock has a market cap of $622.49 million, a P/E ratio of -7.96 and a beta of -0.34. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The firm’s 50-day moving average is $15.09 and its two-hundred day moving average is $12.95.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.